Review

The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response—Biological and Clinical Aspects

Michaela Medová,*, Daniel M. Aebersold, and Yitzhak Zimmer

1 Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, 3010 Bern, Switzerland; E-Mail: daniel.aebersold@insel.ch (D.M.A.)
2 Department of Clinical Research, University of Bern, DKF, MEM-E807, Murtenstrasse 35, 3010 Bern, Switzerland

* Authors to whom correspondence should be addressed; E-Mails: michaela.medova@dkf.unibe.ch (M.M.); yitzhak.zimmer@insel.ch (Y.Z.); Tel.: +41-31-632-2642/3; Fax: +41-31-632-3297.

Received: 1 October 2013; in revised form: 6 December 2013 / Accepted: 6 December 2013 / Published: 19 December 2013

Abstract: Radiation therapy remains an imperative treatment modality for numerous malignancies. Enduring significant technical achievements both on the levels of treatment planning and radiation delivery have led to improvements in local control of tumor growth and reduction in healthy tissue toxicity. Nevertheless, resistance mechanisms, which presumably also involve activation of DNA damage response signaling pathways that eventually may account for loco-regional relapse and consequent tumor progression, still remain a critical problem. Accumulating data suggest that signaling via growth factor receptor tyrosine kinases, which are aberrantly expressed in many tumors, may interfere with the cytotoxic impact of ionizing radiation via the direct activation of the DNA damage response, leading eventually to so-called tumor radioresistance. The aim of this review is to overview the current known data that support a molecular crosstalk between the hepatocyte growth factor receptor tyrosine kinase MET and the DNA damage response. Apart of extending well established concepts over MET biology beyond its function as a growth factor receptor, these observations directly relate to the role of its aberrant activity in resistance to DNA damaging agents, such as ionizing radiation, which are routinely used in cancer therapy and advocate tumor sensitization towards DNA damaging agents in combination with MET targeting.
Keywords: MET; DNA damage response; ionizing radiation; radiotherapy; radioresistance

1. Introduction

The receptor tyrosine kinase (RTK) MET is the cell surface receptor for hepatocyte growth factor (HGF) and is primarily expressed on epithelial cells of many organs during embryogenesis and in adulthood, including the liver, pancreas, prostate, kidney, muscle, and bone marrow [1,2]. Despite being tightly regulated, HGF/MET signaling contributes to oncogenesis and tumor progression in numerous cancers. MET was first identified as an oncogene in 1984 as part of a rare translocation with the nucleoporin translocated promoter region gene (TPR) giving rise to the TPR-MET chimeric oncoprotein [1]. Since this first observation, a variety of additional oncogenic mechanisms that lead to aberrant MET signaling such as overexpression of HGF and/or MET, MET gene amplification and point mutations have been described and extensively characterized in preclinical models [3]. Notably, MET aberrant function does not affect only the tumor cells, but may also exert a crucial impact on the tumor microenvironment, enabling tumor growth and systemic dissemination. In that respect, in vivo studies have shown that activation of the HGF/MET signaling promotes cell invasiveness and triggers metastases through direct involvement in regulation of angiogenesis [4].

As to clinical observations, deregulated MET pathway, primarily due to overexpression, has been observed in many human epithelial cancers, including lung, breast, ovary, kidney, colon, thyroid, liver, and gastric carcinomas [5–12]. MET overexpression results from transcriptional activation, hypoxia-induced overexpression [13], or amplification of the MET gene [14–16]. Importantly, genetic alterations, which generate ligand-independent MET mutants have been found in both hereditary and sporadic papillary renal cell carcinomas and involve mutations in the tyrosine kinase domain of MET [17]. Missense mutations in MET have also been identified in ovarian cancer, childhood hepatoblastoma, metastatic head and neck squamous cell carcinomas, and gastric cancer [18–20]. In melanoma and thoracic malignancies, MET mutations clustered predominantly in the SEMA and juxtamembrane domains [21]. In addition to overexpression and point mutations, MET deregulated activation could also occur via aberrant ligand-dependent mechanisms. Particularly, both tumor and mesenchymal cells can be responsible for increased HGF production, leading to paracrine and/or autocrine mechanisms for receptor activation [22]. This mechanism of enhanced MET signaling has been shown to be tumorigenic and metastatic in athymic nude mice [23].

The prognostic role of HGF and/or MET has been extensively examined (reviewed in [24]). MET/HGF overexpression patterns have been reported to correlate with increased tumor growth rate and metastasis and overall poor prognosis. Apart of its role in tumor pathogenesis, MET/HGF deregulated function emerges as an important resistance mechanism to targeted therapies against other oncogene systems such as that of the epidermal growth factor receptor (EGFR) (reviewed in [25]). Moreover, an increasing body of evidence is suggesting that apart of controlling biological consequences that are typically associated with signaling of a growth factor receptor, MET signaling may also be wired with critical pathways of the DNA damage response. These findings are extremely important as they may identify aberrant MET function as an important determinant of resistance of tumor cell response to DNA
damaging agents (DDAs) widely used in cancer treatment such as ionizing radiation (IR), the main clinical tool of radiation therapy. In the current manuscript, we aim to review the current data linking MET and tumor cells response to IR.

2. Results and Discussion

2.1. Radiotherapy

Radiation therapy (RT), whose highly efficient tumoricidal effect is elicited primarily through infliction of DNA damage, is an integral clinical modality that uses high-energy radiation such as X-rays, gamma rays, and charged particles for the treatment of numerous solid tumors [26]. According to the National Cancer Institute, approximately half of all cancer patients receive radiation as a part of their treatment. Ongoing technical developments during recent years in both treatment planning and radiation delivery have led to improvements in local control of tumor growth and reductions in toxicity [27]. However, treatment failure, due to resistance mechanisms, which presumably involve activation of DNA damage response (DDR) signaling pathways that account for loco-regional relapse and consequent tumor progression still remain a critical problem [28]. Understanding the biology underlying these resistance mechanisms is essential for the development of novel combination therapies [29].

Unlike systemic treatments, the impact of RT is local. Although RT affects healthy tissue as well, normal cells can usually repair more effectively DNA damage via the activation of repair as well as checkpoint controls machineries, which are severely compromised in cancer cells [26]. RT is used either as a curative approach, or as a palliative way to reduce cancer symptoms for advanced cancers. RT is also practiced on a prophylactic basis, in order to prevent spreading of tumor cells, following for example surgery [30]. Furthermore, RT is often delivered as pre-operative or adjuvant therapy, also in combination with other anticancer therapies (chemoradiotherapy) [31,32].

RT may be primarily administered either by using a beam delivered by an external irradiation source or internally, by inserting a solid radioactive isotope close to or inside the tumor for limited period of time, a method widely known as brachytherapy. In addition and in particular cases, radioactive isotopes, as radioactive iodine $^{131}$I, are given systemically for the treatment of particular malignant disorders, such as thyroid cancer. External RT is normally given as a series of short treatments by linear accelerators. Dividing the treatment in 30–35 daily fractions (or as hyperfractionated or accelerated therapy) over 6–7 weeks ensures that less damage is inflicted to normal cells than to cancer cells. The damage to normal cells, affecting predominantly tissues in which cells are dividing more rapidly, is mainly temporary, but is a major reason why radiotherapy does have side effects.

As radiation is a local treatment, side effects are usually confined to the treated area. Early effects such as mucositis and affected skin may be seen already few days or weeks following treatment start and may continue for several weeks after treatment has ended. Other consequences such as radiation-related chronic inflammation and tissue fibrosis may not show up until months, or even years later and may include also secondary cancers. Nevertheless, advanced state of the art delivery technologies, such as three-dimensional conformal radiation therapy, intensity modulated radiation therapy, conformal
proton beam radiation therapy, stereotactic radiosurgery or brachytherapy do increase RT safety with considerable better results [29].

Nonetheless and despite these progresses, treatment outcome for numerous malignancies remain grim, with distant metastases and locoregional tumor progression being the main reasons for treatment failure. Areas of intense radiation research over the last decade have included modified fractionation, integration of chemotherapy, high-precision beam delivery and biological targeting.

Whether a tumor can be cured by IR depends to a large extent on the number and radiation sensitivity of clonogenic tumor cells [33] but also on various other factors which contribute to the response to radiation such as repopulation, cell cycle control and naturally, the ability to repair damaged DNA. Additionally, it is well established that hypoxic tumors exhibit considerable compromised IR-induced cytotoxicity [34]. Better understanding of the molecular basis of radiation resistance will hopefully contribute to the identification of molecules driving these processes and, subsequently, to development of pharmacological compounds that can be used for specific targeting. The proof of this concept has been demonstrated using EGFR inhibitors in head and neck cancer, which represents a role model for modern, biologically optimized radiotherapy [29,35]. However, cancer relapse due to therapeutic resistance and development of distant metastases constitutes a major impediment to effective treatment.

2.2. The DNA Damage Response

The DDR machinery comprises of multiple coordinated checkpoint and repair pathways, which detect DNA lesions and signal their presence to numerous effectors participating in the DDR to ensure prompt repair of the damaged DNA. The cellular response to DNA damage is divided into processes that essentially signal into checkpoint regulation and apoptosis on one hand and execution of DNA repair on the other hand. The central components of the signal transduction response are the phosphoinositol-3-kinase-like Ataxia telangiectasia and Ataxia telangiectasia and Rad3-related kinases kinases, ATM and ATR, respectively [36–38]. Cells harboring DNA damage that maintain intact cell cycle checkpoints such as TP53 usually proceed to a cell cycle arrest to enable accurate DNA repair. If the DNA damage is excessive, cells may undergo apoptosis or senescence. On contrary, cells with compromised checkpoint signaling (e.g., mutated TP53) may continue to cycle, accumulating potentially more DNA damage with an ultimate increase of genomic instability, which eventually can contribute to a more aggressive malignant phenotype [39–41].

ATM is activated in response to DSBs and it relocates through an interaction with the MRE11-RAD50-NBS1 (MRN) complex to sites of DNA breaks [42]. ATM molecules exist as inactive dimers that, when recruited to DSBs, dissociate and autophosphorylate on multiple residues including Ser1981. Subsequently, ATM phosphorylates histone H2AX on Ser139 to generate the phosphorylated form γH2AX, as well as many other substrate proteins including Artemis, MDC1, NBS1, TP53, CHK2 and DNA-PKcs. These proteins further activate cell cycle checkpoints and repair pathways.

ATR is recruited to single-stranded DNA (ssDNA) regions, which arise at stalled replication forks or during the processing of bulky lesions such as UV photoproducts [43]. Stalling of DNA polymerases leads to the generation of ssDNA and subsequent interaction with the single-strand binding replication protein A (RPA). The ssDNA-RPA complex recruits the ATR protein through its regulatory subunit
ATRIP and it recruits and activates the RAD17 clamp loader. RAD17 loads the PCNA-related 911 complex onto DNA.

Mediator proteins downstream of ATM/ATR kinases serve both as recruiters of additional substrates and as scaffolds for the assembly of protein complexes, which eventually participate in the repair of lesions. In recent years, MDC1, 53BP1, the MRE11-RAD50-NBS1 (MRN) complex, Claspin, BRIT1/MCPH1, BRCA1, and other proteins were discovered and classified as DDR mediators [44]. In addition to signaling, many proteins involved in DDR, including ATM and H2AX, form nuclear foci, marking thereby the sites of DNA damage.

To maintain genome integrity, the cell relies on complex signaling networks to coordinate cell-cycle checkpoints that, in response to DNA damage, allow for the cell cycle to arrest and DNA repair to proceed, or, on the other hand, activate senescence or cell death pathways. The cascade that results in cell cycle arrest and DNA repair is instigated by the activation of ATM and ATR [45–49]. Checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2) are serine-threonine kinases downstream of ATR/ATM and play a critical role in initiating cell cycle arrest after DNA damage, allowing time for DNA repair and cell survival. In general, cell cycle arrest is achieved by the inactivation of CDC25 phosphatase family members via the phosphorylation by CHK1/CHK2 reducing thereby cyclin-dependent kinase activity needed for cell cycle progression [50].

More specifically, after its activation (predominantly by ATR via phosphorylation of Ser317 and Ser345), CHK1 phosphorylates serine residues on the protein phosphatase CDC25a, which leads to CDC25a ubiquitination and proteolysis. This way, the ability of CDC25a to drive the progression through the S-phase is limited. CHK1 also phosphorylates CDC25c, preventing dephosphorylation and activation of CDK1 what finally results in cell cycle arrest in the G2 phase. CHK2 [51] is believed to be activated mainly by ATM by phosphorylation on Thr68 and its effects on the effector proteins CDC25a, CDC25b/c, and TP53 are similar to those mediated by CHK1.

Although CHK1/CHK2 effects on downstream pathways share some similarities and crosstalk between them has been demonstrated in some studies [52], currently it is assumed, that G1 checkpoint is modulated primarily by the ATM-CHK2-TP53 pathway, as the expression of ATR, CHK1, and CDC25a is limited until the cell passes the restriction point [53]. On the other hand, the importance of CHK1 lies in the regulation of the S, intra-S, and the G2-M phase checkpoints. Since the majority of tumors are deficient in the G1 DNA damage checkpoint pathway due to mutations in TP53 or the loss of this protein, they rely on S and G2 phase checkpoints for DNA repair and survival. Thus, the modulation of the DNA checkpoint pathways, particularly the inhibition of CHL1, offers the potential to sensitize cancer cells to DNA damage induced by chemotherapeutics and radiotherapy [54]. The potency of this anti-cancer approach is being widely tested by the use of several checkpoint kinase inhibitors, from which three (XL-844, AZD7762, and PF00477736) have already entered clinical trials [55].

DNA repair mechanisms have evolved to respond and remove DNA lesions in order to maintain genetic stability. Defects in DNA repair cause hypersensitivity to DDAs, accumulation of mutations in the genome, and ultimately lead to the development of a broad array of genetic disorders, including cancer. Eucaryotic cells have several mechanisms to restore the structural integrity of DNA [56]: Direct Damage Reversal involves several protein activities that recognize very specific modified bases, typically methylated, and repair defects (such as O6-alkylguanine, O4-alkylthymine) by transferring the
modifying group from the DNA to themselves. Three Excision Repair (ER) modes include nucleotide ER which fixes bulky lesions such as pyrimidine dimers, base ER machinery which repairs damaged bases and SSBs, and mismatch ER, a multienzyme system which corrects mismatched nucleotides and small loops occurring during replication. Homologous Recombination (HR) faithfully repairs DSBs while more often executed nonhomologous end-joining (NHEJ) repairs DSBs in an error-prone way.

Recent studies of the consequences of diminished capacity for DNA repair in humans have linked many human diseases with its decreased functionality of DNA repair [57]. For example, inherited defects in mismatch repair enzymes (e.g., MSH2, 3, 6, MLH1) are linked to colon cancer development. Ataxia telangiectasia, a syndrome in which DSB repair kinase ATM is mutated, is connected with leukemia, lymphoma, radiation sensitivity and genome instability, xeroderma pigmentosum, a disease where NER is affected, displays UV sensitivity and a skin cancer phenotype.

Among the DNA repair machineries, primarily BER, HR, and NHEJ were shown to function in repair of radiation-induced DNA lesions. Specifically, BER is involved in processing the base damage, AP sites, multiply damaged sites, and SSBs, and HR and NHEJ play a role in the repair of DSBs.

2.3. Growth Factor RTK Systems Involved in Responses to DNA Damage

2.3.1. EGFR

The most characterized RTK system involved in cellular responses to DNA damage inflicted by DDAs such as IR is that of the EGFR. In the 1990s, studies initiated by the laboratory of Rupert Schmidt-Ullrich were the first to observe that irradiation of cancer cells impacts EGFR signaling [58–60]. In that respect, this group reported that exposure of A431 squamous carcinoma cells to IR, using clinically relevant doses, activated the tyrosine kinase enzymatic activity of the EGFR as indicated by the receptor ability to undergo autophosphorylation, similarly, albeit to a lesser extent as by its activation by EGF [58]. Moreover, in the same cells, IR led also to activation of the MAPK pathway, which is tightly associated with cell proliferation. Indeed, the same authors found that a single exposure of A431 cells to irradiation doses that ranged between 0.5 and 5 Gy was sufficient to result in cellular growth and proliferation [58]. In one of the first examples that would suggest a radiosensitization potential by means of EGFR targeting, the study has shown that by using the tyrphostin AG1478, one of the first EGFR kinase inhibitors, it was possible to block IR-dependent EGFR downstream signaling and associated tumor cell proliferation. Mechanistically, Dent et al. have shown in both A431 cells and in the breast cancer line MDA-MB-231 that IR-related EGFR activation with consequent cellular proliferation and cytoprotective consequences is modulated via an autocrine loop driven by release of the EGFR ligand, transforming growth factor α (TGFα), with subsequent activation of the MAPK and JNK pathways [61]. Neutralization of TGFα by anti-TGFα antibodies or inhibition of MAPK function by the MEK1/2 inhibitors PD98059 and U0126 resulted in radiosensitization towards IR. As what seems to be the first successful in vivo xenograft model, Lammering et al. have used MDA-MB-231 cells that overexpress a dominant-negative EGFR mutant, EGFR-CD533, to demonstrate the rationale of blocking of the EGFR for tumor radiosensitization in a pre-clinical setup [62]. Although the few studies described so far suggested a link between IR and EGFR activation (Table 1), establishing therefore a sound biological rationale for EGFR targeting as a radiosensitization modality, they still did
not proof a direct link between this RTK system and DDR-associated signaling. The first clue for such a potential crosstalk was provided in a 1998 study by Bandyopadhyay et al. who demonstrated a physical interaction between the EGFR and the catalytic subunit of DNA-dependent protein kinase (DNA-PK), a major effector of DNA double strand breaks (DSBs) repair via the non-homologous end join repair (NHEJ) pathway [63]. Moreover, by using the EGFR monoclonal antibody C225 (later cetuximab), these authors managed to detect a significant decrease of 75% in DNA-PK nuclear activity, potentially showing that an interference with EGFR may affect an important DDR activity. In a follow-up study by the Harari group, Huang et al. demonstrated the in vivo radiosensitizing effects of C225 in models of human squamous cell carcinomas when combined with IR [64]. The authors observed that C225 induced a redistribution of DNA-PK from the nucleus to the cytosol, suggesting therefore one possible mechanism whereby C225 may influence the cellular response to radiation via EGFR targeting. In further support of the involvement of EGFR signaling in response to DNA damage, Yacoub et al. reported a MAPK-dependent up-regulation of the DNA repair proteins ERCC1 and XRCC1 in human prostate cancer cell lines and that this induction could be decreased via EGFR targeting by A1478 [65]. Additional mechanistic evidence directly linking EGFR with DDR signaling has been provided in 2005 by Dittmann et al. who showed an IR-dependent nuclear translocation of an EGFR–DNA-PK complex in human lung cancer cells A459. Exposure of the cells to C225 interrupted DNA-PK translocation and IR-induced phosphorylation with subsequent attenuation of DNA repair and reduced cellular survival [66,67]. Furthermore, by targeting EGFR with the small molecule erlotinib, Li et al. demonstrated impairment of DSBs homologous recombination repair via cytoplasmic sequestration of BRCA1, which plays a critical role in this repair pathway [68]. As to the proof of principle for the potential translational benefit of EGFR inhibition for tumor radiosensitization in context of a clinical setup, Bonner et al. provided the first evidence in their seminal N. Engl. J. Med. manuscript of 2006 [69]. In this study, cetuximab combined with RT exhibited significant results in patients with head and neck tumors. The authors reported that the combination of the two modalities significantly improved both locoregional tumor growth control as well as overall survival as compared to results seen with each modality alone.

Before concluding this chapter in which we covered only partially the data that supports the existence of an EGFR-DR crosstalk signaling, it might be worthwhile mentioning the significance of EGFR mutations to this crosstalk. In that respect, two manuscripts from the Nirodi group focused on the relevance of EGFR mutations to the response of non-small cell lung cancer (NSCLC) cell lines to IR. NSCLCs harboring mutations in the EGFR TK domain represent a subtype of these tumors that exhibit very high sensitivity to EGFR inhibitors, probably due to the addiction towards this RTK system [70–76]. In a 2006 published article, Das et al. have first reported that that NSCLC lines with EGFR TK mutations such as L858R or the E746-E750 deletion mutant exhibit a dramatic increased sensitivity towards IR as compared with tumors cells that express the WT form of the receptor [77]. In a follow-up 2007 study, the same authors reported that this hypersensitivity results from reduced EGFR radioprotective ability due to a defective interaction between mutated EGFR forms with DNA-PK and subsequent IR-related nuclear translocation [78].

Collectively, these as well as findings from other studies provided solid data suggesting that EGFR is a potential regulator of tumor cells response to DNA damage and support the biological rationale for its targeting along with DDAs.
2.3.2. IGF-1R

Apart of the EGFR, several other RTK systems have been associated with cancer cells response to DNA damage (Table 1) and hence are considered as molecular targets for tumor radiosensitization. The insulin-like growth factor 1 receptor (IGF-1R) is an emerging target in molecular oncology as it is overexpressed in many types of human cancers [79–83]. The first indications that IGF-1R may correlate with tumor response to RT originate from a 1997 manuscript by Turner et al. who reported that breast tumors with IGF-1R overexpression correlate with early local relapse within 4 years of lumpectomy and irradiation, suggesting that IGF-1R aberrant expression is associated with radioresistance [84]. This conclusion was further supported by the demonstration that IGF-1R overexpression in murine fibroblasts conferred radioresistance. Radiosensitivity was restored by downregulating IGF-1R expression using antisense (AS) oligonucleotides [84]. In a following study in 2001 by Macaulay et al., the authors provided evidence that melanoma cells expressing IGF-1R AS are more sensitive to IR. A clue that IGF-1R downregulation may sensitize tumor cells via interference with function of the DDR has been suggested by the same group with the finding that IGF-1R AS-expressing cells exhibited lower levels of the DDR master upstream kinase ATM [85]. Additional solid mechanistic basis in that respect has been reported by Peretz et al. also in 2001 [86] by investigating the IGF-1R expression status in A-T cells, which exhibit extreme sensitivity to IR [87]. The study has shown that A-T cells display low levels of IGF-1R and complementation of these cells with ectopic IGF-1R expression conferred cells with higher resistance towards IR. Further data supporting an IGF-1R-DDR link have been furnished by the Reiss group, who demonstrated that IGF-1R signaling controls intracellular trafficking of the RAD51 recombinase, which is a critical homologous recombination effector [88]. All together, these findings serve as evidence-based data supporting a molecular crosstalk between this RTK system and cellular response to RT and provide a biologic rationale for the use of inhibitors for sensitization of IGF-1R-positive tumors towards RT. Indeed, in a 2007 manuscript, Allen et al. have shown radiosensitization of tumors cells, particularly of NSCLC origin to IR using A12, a fully humanized anti-IGF-1R monoclonal antibody. A12 was found to inhibit DSBs repair as manifested by sustained expression of γH2AX [89]. Similar results were recently reported by Riesterer et al. that used head and neck cancer cells [90].

2.3.3. VEGFR, PDGFR, FGFR

Clues suggesting the potential involvement of additional tyrosine kinase receptors such as those for vascular endothelial growth factors (VEGFRs), platelet-derived growth factors (PDGFRs) and fibroblast growth factors (FGFRs) in response of tumor cells to DNA damage emerge particular from studies that demonstrated tumor cells radiosensitization by using inhibitors for these receptors. In that respect for example, SU6668 is a small molecule inhibitor of the angiogenic RTKs, VEGFR2 (Flk-1/KDR), PDGFRβ and FGFR1 [91]. By employing xenograft models of fibrosarcoma and pancreatic carcinoma cells lines, Griffin et al. have reported that SU6668 administration for 2 days followed by a single dose of 15 Gy of X-irradiation was significantly more effective in suppressing tumor growth than either treatment alone [92]. Analogous data have been reported by Ning et al. [93]. In 2003, Abdollahi et al. reported that IR-associated tumor growth due to VEGF secretion with
consequent pro-angiogenic impact on endothelial cells could be attenuated by both SU6668 and SU5416 [94]. Unlike the multi-kinase inhibition properties of SU6668, SU5416 (semaxanib) is a potent and selective inhibitor of VEGFR2 [95,96]. Using a combination of both SU6668 and SU5416 with relatively low IR doses, Timke et al. reported better tumor control in xenograft models of prostate cancer and glioblastoma lines [97]. This has been attributed to the high cytotoxicity of the combined treatment on the endothelial cell compartment as judged from the excessive apoptotic rate measured by caspase-3 activity.

### Table 1. Observations linking RTK systems to cellular DDR.

| DDR-related protein                        | RTK       | Mode of modulation                                                                 |
|-------------------------------------------|-----------|--------------------------------------------------------------------------------------|
| DNA-PK (dsDNA breaks repair by non-homologous end-joining) | EGFR      | physical interaction [63], lower DNA-PK nuclear activity [63] and redistribution of DNA-PK from nucleus to cytosol upon EGFRi [64], EGFR in complex with DNA-PK [67], IR-dependent nuclear translocation of EGFR [67], defective interaction with EGFR mutants [78] |
| ERCC1 (ssDNA breaks repair by nucleotide excision) | EGFR      | MAPK-dependent upregulation [65]                                                      |
| XRCC1 (ssDNA breaks repair by base excision) | EGFR      | MAPK-dependent upregulation [65]                                                      |
| BRCA1 (dsDNA breaks repair by homologous recombination) | EGFR      | cytoplasmic sequestration upon EGFRi [68]                                            |
| ATM (dsDNA damage breaks sensing)          | IGF-1R, MET | lower levels in IGF-1R antisense-expressing cells [85], A-T cells display low levels of IGF-1R [86], MET-dependent ATM activation upon IR [98], increase in ATM autophosphorylation upon METi [99] intracellular trafficking controlled by IGF-1R [88], decrease in phosphorylation and nuclear translocation upon METi [100], interaction with BRCA2 hindered upon METi [101], reduced levels upon METi combined with IR [102] |
| RAD51 (dsDNA breaks repair by homologous recombination) | IGF-1R, MET | interaction with RAD51 hindered by METi [101]                                         |
| BRCA2 (dsDNA breaks repair by homologous recombination) | MET       | interaction with RAD51 hindered by METi [101]                                         |
| γH2AX (dsDNA damage breaks sensing)        | IGF-1R, MET | sustained γH2AX expression upon IGF-1R [89] and MET [99] inhibition, sustained γH2AX levels upon METi in combination with IR [99] |
2.4. Activation of HGF-MET Axis Protects Cells from DDAs-Related Cytotoxicity

The initial indications for a potential involvement of signaling by the MET RTK in cellular responses to DNA damage (Figure 1) emerged in the late 1990s with several publications by the group of Elliot Rosen. In 1998, Fan et al. reported an HGF-mediated tumor cells survival, which was correlated with decreased expression of the pro-apoptotic protein, Bcl-X\textsubscript{L}, following exposure to various DDAs, including IR and the topoisomerase II\textalpha inhibitor adriamycin (ADR) [103]. In a subsequent study, the same group suggested that pre-treatment of human cancer cell lines with HGF enhanced in a PI3K-dependent manner their DNA repair activity towards both single and double strand DNA lesions [104]. Aiming at more mechanistic insights and by using the MDCK cell line as an experimental model, Fan et al. interestingly reported that the MET principal downstream signaling adaptor GAB1 is actually a negative regulator of HGF/MET-mediated DNA repair [105]. This inhibitory function did not require the GAB1 pleckstrin homology or SHP2 phosphatase-binding domain essential for MET/GAB1-mediated epithelial morphogenesis [106] but did require its PI3K-binding domain. In order to reveal alterations in gene expression that might contribute to HGF/MET-mediated cell protection and responses to DDAs, the same authors have used a cDNA microarray and a semi-quantitative RT-PCR approach, using the MDA-MB-453 human breast cancer cells that were incubated with HGF prior to ADR exposure [107]. Among various changes in gene expression patterns following HGF treatment, this study identified an induction of expression of the polycystic kidney disease 1 (PKD1) gene, which encodes a pro-survival constituent of cadherin-catenin complexes, which is downregulated upon ADR treatment. On the other hand, MET activation prior to ADR administration resulted in downregulation of such genes as 51C, an inositol polyphosphate 5-phosphatase, TOPBP1, which is a topoisomerase IIB-binding protein and the Rho-like small GTPase protein CIP4 [107]. A more detailed molecular significance of these changes in the context of a potential MET-DDR crosstalk has yet to be further investigated. In the studies that have been quoted so far, exogenous application of HGF has been shown to promote cellular survival towards DDAs. In a 2007 study, Sheng-Hua et al. showed a dose-dependent increase in HGF levels in the media of several glioma cells after a single dose radiation [108]. The authors identified that both baseline and radiation-enhanced HGF levels were about 10-fold higher in the BT325 cell line compared with other cell lines in the study. Interestingly, by employing a cell proliferation assay, the BT325 was more radioresistant than cell lines, which displayed a more moderate increase in IR-dependent HGF levels. As postoperative radiotherapy is a standard treatment for patients with malignant glioma and as these tumors display radioresistance and often relapse, even after a high dose of radiation, the authors suggested these in vitro observations as a potential relevant mechanism for HGF-mediated radioresistance of gliomas in clinical setups. In a similar work using pancreatic cell lines, Qian et al. monitored changes in MET levels and biologic activity following irradiation [109]. The authors reported an IR-related increased MET expression starting 3 hours post irradiation and reaching its peak 24 h later. Upon adding HGF, a MET-dependent MAPK activity associated with cellular scattering and invasion has been shown, however, without increase in cell proliferation [109].
2.5. Clinical Observations Correlating MET Expression with Responses to RT

While a large body of evidence supports tumor-associated MET signaling with cancer pathogenesis and progression [110,111], only few studies provided so far clues for a potential correlation between MET aberrant activity and responses to RT in clinical setups. In that respect, the 2001 report by Aebersold et al. was probably the first to suggest that MET expression is an independent and significant predicting factor of impaired local free-survival in a cohort of 97 patients with squamous cell carcinoma of the oropharynx who underwent definitive RT [112]. By employing an immunohistochemical analysis of various prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy, Kim et al. identified high MET expression levels as a statistically significant negative prognostic factor on survival [113]. MET deregulated expression has been suggested to serve as a biomarker for tumor recurrence. Thus, overexpression of MET in hepatocellular carcinoma tissue or sustained high level of HGF in serum after hepatectomy were reported to relate with early tumor recurrence and metastasis [114]. Similarly, Raghav et al. reported in 2012 that high levels of phosphorylated MET are associated with increased risk of recurrence in patients with breast cancers [115]. Analogous observation regarding MET expression as a risk for tumor recurrence have been reported also for patients with carcinoma of the tongue [116].

Figure 1. MET-downstream signaling activated by HGF stimulation prior to DNA damage and involved in MET-driven protection of cancer cell from DDAs.

In a 2000 manuscript, Di Renzo et al. reported a correlation between MET somatic mutations and lymph nodes metastasis in patients with head and neck squamous cell carcinomas (HNSCCs) [117]. As MET mutated variants exhibit also ligand-independent receptor enzymatic activity and since HGF was shown to protect tumor cells from DDAs [104], Aebersold et al. screened samples from HNSCC patients who were treated by radical RT for a correlation between presence of the MET Y1253D variant and responses to RT [118]. MET Y1253D has been identified in 15 out of a cohort of 138 patients. Both univariate and multivariate survival analysis revealed MET Y1253D to be significantly associated with impaired local tumor control. These findings provided evidence that the MET somatic mutation
Y1253D is present in a notable subset of HNSCC patients and pointed out that this mutation may interfere with radioresponsiveness of these tumors, supporting further the notion of aberrant MET signaling as a target for radiosensitization.

2.6. Potentiation of IR-Induced Cytotoxicity by Targeting MET Signaling

MET targeting in cancer therapy has emerged as a major concept over the last decade with approximately 20 different selective as well as non-specific MET tyrosine kinase inhibitors (TKIs) and monoclonal antibodies that have been reported so far [119,120] out of which about 10 are currently in different phases of clinical trials [111]. Here, we will focus on the approaches that have been combined along with IR and that were discussed in the context of radiosensitization.

The Laterra group was the first to show in 2005 that targeting the MET pathway considerably potentiates tumor response towards IR [121]. By using anti-MET or anti-HGF ribozymes in a U87 glioblastoma xenograft model, the authors reported 0% response to irradiation alone and 20% response in animals that received intracranial delivery of the corresponding ribozymes. Animals that got a combined treatment exhibited an impressive 80% rate response. Moreover, combining the therapies led to tumor regression with a 40% tumor cure rate. Later, Chu et al. demonstrated both in vitro and in vivo and by using the U251 glioblastoma cell line a potentiation of IR-induced cytotoxicity by MET antisense oligonucleotides [122]. With respect to targeting MET pharmacologically, Welsh et al. found that the MP470 small molecule inhibitor considerably enhanced radiation-induced cell killing in SF767 cells [102]. Similarly, reduced clonogenic survival of gastric carcinoma cells GTL-16 has been reported by our group, using the indoline-2-one core anti-MET compound PHA665752 [99]. Other studies providing comparable data have used the MET small molecule inhibitors SU11274, MK-8003 and AMG548 [123–125], as well as the MET monoclonal antibody rilotumumab/AMG102 [126].

2.7. A Potential Molecular Crosstalk between MET and the DDR

Probably the most compelling data regarding how MET signaling may affect tumor resistance to DDAs, and in particular to IR, is related to the impact of MET signaling on the DDR apparatus, and in particular pathways involved in DNA repair (Table 1, Figure 2). In a manuscript published in 2008 [100], Ganapathipillai et al. suggested a signaling axis between mutated MET variants, the non-receptor tyrosine kinase ABL and the RAD51 recombinase, a critical HR DSBs repair effector [127]. The study showed that inhibition of MET tyrosine kinase activity by SU11274 was accompanied by reduction of phosphorylation of RAD51 on tyrosine 315, a residue whose phosphorylation has been associated with RAD51 nuclear translocation upon DNA damage [128,129]. Indeed, MET inhibition was further associated with impairment of nuclear translocation of a RAD51-GFP chimeric protein following irradiation. These events had also consequences on DNA repair as demonstrated by the ability of SU11274 to delay decline in γH2AX levels, indicating inhibition of DSBs repair [100]. In a follow-up paper, Medová et al. used a DR-GFP assay to demonstrate that MET targeting by PHA665752 or by specific siRNAs inhibited the ability of the corresponding cells to properly execute DSB repair via HR [101]. Mechanistically, treatment by the same drug has been found to disrupt the formation between RAD51 and BRCA2, an event, which is critical for HR to take place [101]. These data are very much similar with the aforementioned study by Li et al. who reported HR inhibition via EGFR
inhibition by erlotinib [68]. Another indication for the negative impact of MET inhibition on DSBs repair has been provided by Welsh et al. who reported increased γH2AX foci with reduced RAD51 levels upon combination of IR with the small molecule inhibitor MP470 [102]. In an attempt to investigate in further details the interaction between MET and the DDR, Medová et al. described in a 2010 study a synergistic mode of interaction between PHA665752 and IR [99]. Importantly, it has also been found, as a potential molecular mechanism underlying this synergism, that MET inhibition alone was sufficient to increase γH2AX levels in GTL-16 gastric cancer cells, strongly indicating that MET signaling may be involved in repair of DNA damage of endogenous replicative stress origin [99]. If further confirmed, such a finding may at least partially account for the synergism between MET targeting and IR, as inhibition of the DNA repair driven via MET may compromise the ability of cells to repair the damage inflicted via irradiation.

**Figure 2.** DDR sensors, mediators and effectors that have been shown to be modulated by MET signaling and/or MET inhibition alone or in combination with DDAs (full lines—direct links, broken lines—links that have not been proven direct).

In two *Nature* articles published in 2009, Xiao et al. and Cook et al. reported tyrosine 142 as a novel regulatory site of H2AX whose phosphorylation and subsequent dephosphorylation are executed by the WIHC complex and the EYA1/3 phosphatases, respectively [130,131]. H2AX tyrosine phosphorylation was suggested to function as a novel regulatory mechanism, which affects histone associations with either pro-apoptotic or repair factors. Overall, lasting tyrosine phosphorylation was shown to correlate with H2AX recruitment of pro-apoptotic effectors such as the JNK1 kinase, eventually leading to apoptosis. Interestingly, when MET activity was targeted in GTL-16 by PHA665752, alone or in combination with irradiation, a massive increase of H2AX phosphorylation on tyrosine 142 with the subsequent interaction with the pro-apoptotic kinase JNK1 has been observed, providing therefore
an additional mechanistic aspect of how MET inhibition contributes to a compromised cellular response towards IR.

More supportive findings on the potential role of MET for cellular responses to DDAs has been recently provided by De Bacco et al. who demonstrated that IR affects the expression and activity of MET [98]. After irradiation, MET expression in breast cancer cell lines was increased up to fivefold, and this overexpression increased ligand-independent MET phosphorylation and signal transduction, which protects cells from apoptosis [98]. Cells that survived irradiation also became increasingly invasive, an effect that was driven through activation of ATM and nuclear factor κB (NF-κB) signaling pathways.

Finally and in addition to that effects that MET inhibition has on DNA repair, a 2010 study by Medová et al. investigated potential impact of PHA665752 on the checkpoint control arm of the DDR [99]. In that context, this drug showed a MET-dependent inhibition of ATR, CHK1, and CDC25B with consequent abrogation of an associated DNA damage–induced S phase arrest. This may indicate that MET inhibition compromises a critical damage dependent checkpoint that may enable premature exit of DNA-damaged cells from cell cycle arrest before repair is completed.

2.8. The Relevance of MET Signaling to Tumor Resistance towards RT under Hypoxic Conditions

Poor oxygenation is a common feature of solid tumors. On one hand, deregulated growth overrides the ability of the vasculature to adapt to the increased oxygen demand [132,133]; on the other, tumor blood vessels are functionally impaired compared to normal tissues due to structural and biological abnormalities such as leakiness and lack of pericytes [134]. As a result, neoplastic lesions often contain areas subjected to acute or chronic hypoxia regardless of blood vessel proximity [135].

Oxygen insufficiency limits the growth of the tumor, because cancer cells, as other cells in the organism, utilize oxygen to generate energy and as a substrate for a number of fundamental biochemical processes including synthesis of macromolecules. On the contrary, however, and somehow in contrast to expectations, overwhelming experimental and clinical evidence suggests that hypoxic tumors are more aggressive than well-oxygenized lesions and that their prognosis is less favorable [34,136–140]. This is currently attributed to the fact that hypoxia induces a number of cellular adaptations that may turn advantageous during tumor progression, including a switch to anaerobic metabolism [141], increased genetic instability [142], promotion of angiogenesis [143], activation of invasive growth [13] and preservation of stem cells features [144].

Apart of its impact on tumor growth and progression, hypoxia also represents a major obstacle for radiotherapy as hypoxic cells are approximately three-fold more resistant than well-oxygenated cells [140]. Furthermore, hypoxia has similar resistance effects on the response of tumors to anti-cancer drugs that elicit their pharmacological effect on oxygen-generated free radical species [145].

The biological effect of radiation depends on the degree of oxygenation. This oxygen effect is due to the interaction between oxygen and the free radicals produced when radiation is absorbed in tissues. These highly reactive, short-lived free radicals produce DNA DSBs, leading eventually to cell death. Oxygen amplifies the damage produced by radiation by increasing the lifetime of free radicals. Due to their short life-span, oxygen needs to be present at the time of irradiation to be effective [146,147]. In that respect, several studies showed poor locoregional control and survival in patients with hypoxic tumors treated with radiation [139,148–152].
Since the discovery of MET and its ligand HGF, much research interest has focused on their roles in cancer [153]. Importantly, MET transcriptional activation and deregulated signaling were also shown to have a role in the biology of tumor-associated hypoxia. In 2003, Pennacchietti et al. discovered a molecular mechanism linking hypoxia to increased transcription of the MET gene whose promoter contains several HIF1α-responsive elements [13]. Concomitant to increased expression, upregulation of the MET kinase and its signaling activity have been linked to a deregulated MET-dependent invasive growth program, a finding that could correlate with an increased metastatic potential of hypoxic tumors. In further line with these observations, Hara and colleagues reported in 2006 that HIF-1α siRNA decreased the synergistic activities of hypoxia and HGF on cellular invasion [154].

With respect to the relevance of MET aberrant expression to tumor-related hypoxia in both preclinical and clinical setups, in human cervical cancer xenografts as well as in human breast tumor samples, MET overexpression positively correlated with presence of hypoxic regions [13,155]. Likewise, elevated MET and HIF-1α mRNA expression was observed at the invading front in well-differentiated thyroid papillary carcinoma [156]. HIF-1α expression was also found to significantly correlate with stromal HGF expression and MET expression in human pancreatic adenocarcinoma [157]. Furthermore, MET and HIF-1α expression were reported as independent predictors for distant metastasis and correlated with a poor 10-year disease-free survival rate in breast cancer patients [155]. These studies suggest that hypoxia may enhance signaling of the HGF-MET axis and thereby promote cancer cell metastasis through upregulation of MET expression in vivo. Hypoxia has also been shown to increase HGF-MET signaling, scattering, and invasive activity of cancer cells in vitro. Hypoxic upregulation of MET promoter activity, MET expression and phosphorylation have also been observed in cell lines derived from normal tissues as well as tumors [13,157], while HGF expression and secretion were reported to be increased in hypoxic fibroblasts [157].

Taken together, although tumor hypoxia is known as a critical negative determinant of radiation therapy outcome in several human cancers, the full picture of molecular pathways that contribute to tumor hypoxia-mediated radioresistance remains largely elusive and a better insight into MET signaling under hypoxia with particular emphasis on the receptor crosstalk with DDR pathways and functioning as well as evaluation of the potential of MET inhibitors to increase tumor cells response to therapeutically-relevant irradiation doses under hypoxic conditions needs to be investigated in further details.

3. Conclusions

The MET system whose aberrant activity is found in numerous types of human cancers is considered as a prime target in clinical oncology. In addition to obvious physiological traits that are associated with oncogenic activity of a growth factor receptor such as uncontrolled proliferation, tumor cell survival, local aberrant invasion with eventual systemic dissemination, accumulating data from various studies support the existence of a signaling between MET and the DDR, resembling in that respect other RTKs and in particular, the EGFR.

Apart of extending existing paradigms over the biology of MET as a “classical” growth factor receptor that may also be involved in maintenance of genomic stability, such observations are also critically important with respect to clinical circumstances. Thus, MET may not only serve as a major
determinant of cancer progression in terms of local growth and metastasis, but it may also be an important signaling regulator of responses to DNA damage that can “assist” tumor cells evading RT-induced cytotoxicity. This assumption, that has still to be further confirmed, provides a strong biological rationale for targeting MET in order to obtain more optimal responses to RT and potentially other DDAs of MET expressing tumors. Still, many questions remain at large open and much more studies are required in order to identify the details of the particular pathways through which MET is signaling and wired with the DDR.

Acknowledgments

This work was supported by Swiss National Science Foundation (grant 31003A-125394), Stiftung zur Krebsbekämpfung (Zürich) and by Novartis Stiftung to Yitzhak Zimmer.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Cooper, C.S.; Park, M.; Blair, D.G.; Tainsky, M.A.; Huebner, K.; Croce, C.M.; vande Woude, G.F. Molecular cloning of a new transforming gene from a chemically transformed human cell line. *Nature* **1984**, *311*, 29–33.
2. Bottaro, D.P.; Rubin, J.S.; Falletto, D.L.; Chan, A.M.; Kmiecik, T.E.; vande Woude, G.F.; Aaronson, S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science* **1991**, *251*, 802–804.
3. Iyer, A.; Kmiecik, T.E.; Park, M.; Daar, I.; Blair, D.; Dunn, K.J.; Sutrave, P.; Ihle, J.N.; Bodescot, M.; vande Woude, G.F. Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. *Cell Growth Differ.* **1990**, *1*, 87–95.
4. Zhang, Y.W.; Su, Y.; Volpert, O.V.; vande Woude, G.F. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 12718–12723.
5. Knowles, L.M.; Stabile, L.P.; Egloff, A.M.; Rothstein, M.E.; Thomas, S.M.; Gubish, C.T.; Lerner, E.C.; Seethala, R.R.; Suzuki, S.; Quesnelle, K.M.; *et al.* HGF and c-MET participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. *Clin. Cancer Res.* **2009**, *15*, 3740–3750.
6. Lengyel, E.; Prechtel, D.; Resau, J.H.; Gauger, K.; Welk, A.; Lindemann, K.; Salanti, G.; Richter, T.; Knudsen, B.; vande Woude, G.F.; *et al.* C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of HER2/NEU. *Int. J. Cancer* **2005**, *113*, 678–682.
7. Tokunou, M.; Niki, T.; Eguchi, K.; Iba, S.; Tsuda, H.; Yamada, T.; Matsuno, Y.; Kondo, H.; Saitoh, Y.; Imamura, H.; *et al.* c-MET expression in myofibroblasts: Role in autocrine activation and prognostic significance in lung adenocarcinoma. *Am. J. Pathol.* **2001**, *158*, 1451–1463.
8. Ramirez, R.; Hsu, D.; Patel, A.; Fenton, C.; Dinauer, C.; Tuttle, R.M.; Francis, G.L. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 2000, 53, 635–644.

9. Koochekpour, S.; Jeffers, M.; Rulong, S.; Taylor, G.; Klineberg, E.; Hudson, E.A.; Resau, J.H.; vande Woude, G.F. MET and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997, 57, 5391–5398.

10. Di Renzo, M.F.; Poulsom, R.; Olivero, M.; Comoglio, P.M.; Lemoine, N.R. Expression of the MET/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 1995, 55, 1129–1138.

11. Liu, C.; Park, M.; Tsao, M.S. Overexpression of c-MET proto-oncogene but not epidermal growth factor receptor or c-ERBB-2 in primary human colorectal carcinomas. Oncogene 1992, 7, 181–185.

12. Kelsen, D.P.; Minsky, B.; Smith, M.; Beitler, J.; Niedzwiecki, D.; Chapman, D.; Bains, M.; Burt, M.; Heelan, R.; Hilaris, B. Preoperative therapy for esophageal cancer: A randomized comparison of chemotherapy versus radiation therapy. J. Clin. Oncol. 1990, 8, 1352–1361.

13. Pennacchietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P.M. Hypoxia promotes invasive growth by transcriptional activation of the MET protooncogene. Cancer Cell 2003, 3, 347–361.

14. Cappuzzo, F.; Marchetti, A.; Skolan, M.; Rossi, E.; Gajapathy, S.; Felicioni, L.; del Grammastro, M.; Sciarrotta, M.G.; Buttitta, F.; Incarbone, M.; et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 2009, 27, 1667–1674.

15. Beau-Faller, M.; Ruppert, A.M.; Voegeli, A.C.; Neuville, A.; Meyer, N.; Guerin, E.; Legrain, M.; Mennecier, B.; Wihlm, J.M.; Massard, G.; et al. MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J. Thorac. Oncol. 2008, 3, 331–339.

16. Miller, C.T.; Lin, L.; Casper, A.M.; Lim, J.; Thomas, D.G.; Orringer, M.B.; Chang, A.C.; Chambers, A.F.; Giordano, T.J.; Glover, T.W.; et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006, 25, 409–418.

17. Schmidt, L.; Duh, F.M.; Chen, F.; Kishida, T.; Glenn, G.; Choyke, P.; Scherer, S.W.; Zhuang, Z.; Lubensky, I.; Dean, M.; et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 1997, 16, 68–73.

18. Comoglio, P.M.; Boccaccio, C. Scatter factors and invasive growth. Semin. Cancer Biol. 2001, 11, 153–165.

19. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; vande Woude, G.F. MET, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4, 915–925.

20. Gentile, A.; Trusolino, L.; Comoglio, P.M. The MET tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008, 27, 85–94.
21. Ma, P.C.; Tretiakova, M.S.; MacKinnon, A.C.; Ramnath, N.; Johnson, C.; Dietrich, S.; Seiwert, T.; Christensen, J.G.; Jagadeeswaran, R.; Krausz, T.; et al. Expression and mutational analysis of MET in human solid cancers. *Genes Chromosom. Cancer* **2008**, *47*, 1025–1037.

22. Ferracini, R.; di Renzo, M.F.; Scotlandi, K.; Baldini, N.; Olivero, M.; Lollini, P.; Cremona, O.; Campanacci, M.; Comoglio, P.M. The MET/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. *Oncogene* **1995**, *10*, 739–749.

23. Rong, S.; Segal, S.; Anver, M.; Resau, J.H.; vande Woude, G.F. Invasiveness and metastasis of NIH 3T3 cells induced by MET-hepatocyte growth factor/scatter factor autocrine stimulation. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 4731–4735.

24. Gherardi, E.; Birchmeier, W.; Birchmeier, C.; vande Woude, G. Targeting MET in cancer: Rationale and progress. *Nat. Rev. Cancer* **2012**, *12*, 89–103.

25. Arteaga, C.L. HER3 and mutant EGFR meet MET. *Nat. Med.* **2007**, *13*, 675–677.

26. Moding, E.J.; Kastan, M.B.; Kirsch, D.G. Strategies for optimizing the response of cancer and normal tissues to radiation. *Nat. Rev. Drug Discov.* **2013**, *12*, 526–542.

27. Meyer, J.L.; Leibel, S.; Roach, J.; Vijayakumar, S. New technologies for the radiotherapy of prostate cancer. A discussion of clinical treatment programs. *Front. Radiat. Ther. Oncol.* **2007**, *40*, 315–337.

28. Curtin, N.J. DNA repair dysregulation from cancer driver to therapeutic target. *Nat. Rev. Cancer* **2012**, *12*, 801–817.

29. Baumann, M. Keynote comment: Radiotherapy in the age of molecular oncology. *Lancet Oncol.* **2006**, *7*, 786–787.

30. Rodrigues, G.; Sanatani, M. Age and comorbidity considerations related to radiotherapy and chemotherapy administration. *Semin. Radiat. Oncol.* **2012**, *22*, 277–283.

31. Plataniotis, G.A.; Dale, R.G. Radio-chemotherapy for bladder cancer: Contribution of chemotherapy on local control. *World J. Radiol.* **2013**, *5*, 267–274.

32. Zaorsky, N.G.; Trabulsi, E.J.; Lin, J.; Den, R.B. Multimodality therapy for patients with high-risk prostate cancer: Current status and future directions. *Semin. Oncol.* **2013**, *40*, 308–321.

33. Zhivotovsky, B.; Joseph, B.; Orrenius, S. Tumor radiosensitivity and apoptosis. *Exp. Cell Res.* **1999**, *248*, 10–17.

34. Hockel, M.; Schlenger, K.; Mitze, M.; Schaffer, U.; Vaupel, P. Hypoxia and radiation response in human tumors. *Semin. Radiat. Oncol.* **1996**, *6*, 3–9.

35. Baumann, M.; Krause, M.; Dikomey, E.; Dittmann, K.; Dorr, W.; Kasten-Pisula, U.; Rodemann, H.P. EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. *Radiother. Oncol.* **2007**, *83*, 238–248.

36. Abraham, R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. *Genes Dev.* **2001**, *15*, 2177–2196.

37. Abraham, R.T. PI 3-kinase related kinases: ‘Big’ players in stress-induced signaling pathways. *DNA Repair (Amst.)* **2004**, *3*, 883–887.

38. Shiloh, Y. ATM and ATR: Networking cellular responses to DNA damage. *Curr. Opin. Genet. Dev.* **2001**, *11*, 71–77.
39. Bartek, J.; Bartkova, J.; Lukas, J. DNA damage signalling guards against activated oncogenes and tumour progression. *Oncogene* 2007, 26, 7773–7779.

40. Bartkova, J.; Horejsi, Z.; Koed, K.; Kramer, A.; Tort, F.; Zieger, K.; Guldberg, P.; Sehested, M.; Nesland, J.M.; Lukas, C.; *et al.* DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* 2005, 434, 864–870.

41. Hoeijmakers, J.H. Genome maintenance mechanisms for preventing cancer. *Nature* 2001, 411, 366–374.

42. Lavin, M.F.; Kozlov, S. ATM activation and DNA damage response. *Cell Cycle* 2007, 6, 931–942.

43. Zou, L.; Elledge, S.J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. *Science* 2003, 300, 1542–1548.

44. Harper, J.W.; Elledge, S.J. The DNA damage response: Ten years after. *Mol. Cell* 2007, 28, 739–745.

45. Andreassen, P.R.; Ho, G.P.; D’Andrea, A.D. DNA damage responses and their many interactions with the replication fork. *Carcinogenesis* 2006, 27, 883–892.

46. Zhou, B.B.; Bartek, J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. *Nat. Rev. Cancer* 2004, 4, 216–225.

47. Zhou, B.B.; Elledge, S.J. The DNA damage response: Putting checkpoints in perspective. *Nature* 2000, 408, 433–439.

48. Jazayeri, A.; Falek, J.; Lukas, C.; Bartek, J.; Smith, G.C.; Lukas, J.; Jackson, S.P. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. *Nat. Cell Biol.* 2006, 8, 37–45.

49. Branzei, D.; Foiani, M. Regulation of DNA repair throughout the cell cycle. *Nat. Rev. Mol. Cell Biol.* 2008, 9, 297–308.

50. Karlsson-Rosenthal, C.; Millar, J.B. CDC25: Mechanisms of checkpoint inhibition and recovery. *Trends Cell Biol.* 2006, 16, 285–292.

51. Antoni, L.; Sodha, N.; Collins, I.; Garrett, M.D. CHK2 kinase: Cancer susceptibility and cancer therapy—Two sides of the same coin? *Nat. Rev. Cancer* 2007, 7, 925–936.

52. Zaugg, K.; Su, Y.W.; Reilly, P.T.; Moolani, Y.; Cheung, C.C.; Hakem, R.; Hirao, A.; Liu, Q.; Elledge, S.J.; Mak, T.W. Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. *Proc. Natl. Acad. Sci. USA* 2007, 104, 3805–3810.

53. Stiff, T.; Walker, S.A.; Ceresaletti, K.; Goodarzi, A.A.; Petermann, E.; Concannon, P.; O’Driscoll, M.; Jeggo, P.A. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. *EMBO J.* 2006, 25, 5775–5782.

54. Ashwell, S.; Zabuloff, S. DNA damage detection and repair pathways—Recent advances with inhibitors of checkpoint kinases in cancer therapy. *Clin. Cancer Res.* 2008, 14, 4032–4037.

55. Ashwell, S.; Janetak, J.W.; Zabuloff, S. Keeping checkpoint kinases in line: New selective inhibitors in clinical trials. *Expert Opin. Investig. Drugs* 2008, 17, 1331–1340.

56. Damia, G.; D’Incalci, M. Targeting DNA repair as a promising approach in cancer therapy. *Eur. J. Cancer* 2007, 43, 1791–1801.

57. Pollard, J.M.; Gatti, R.A. Clinical radiation sensitivity with DNA repair disorders: An overview. *Int. J. Radiat. Oncol. Biol. Phys.* 2009, 74, 1323–1331.
58. Schmidt-Ullrich, R.K.; Mikkelsen, R.B.; Dent, P.; Todd, D.G.; Valerie, K.; Kavanagh, B.D.; Contessa, J.N.; Rorrer, W.K.; Chen, P.B. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. *Oncogene* 1997, 15, 1191–1197.

59. Schmidt-Ullrich, R.K.; Valerie, K.; Fogleman, P.B.; Walters, J. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. *Radiat. Res.* 1996, 145, 81–85.

60. Contessa, J.N.; Reardon, D.B.; Todd, D.; Dent, P.; Mikkelsen, R.B.; Valerie, K.; Bowers, G.D.; Schmidt-Ullrich, R.K. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. *Clin. Cancer Res.* 1999, 5, 405–411.

61. Dent, P.; Reardon, D.B.; Park, J.S.; Bowers, G.; Logsdon, C.; Valerie, K.; Schmidt-Ullrich, R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. *Mol. Biol. Cell* 1999, 10, 2493–2506.

62. Lammering, G.; Hewit, T.H.; Hawkins, W.T.; Contessa, J.N.; Reardon, D.B.; Lin, P.S.; Valerie, K.; Dent, P.; Mikkelsen, R.B.; Schmidt-Ullrich, R.K. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. *J. Natl. Cancer Inst.* 2001, 93, 921–929.

63. Bandyopadhyay, D.; Mandal, M.; Adam, L.; Mendelsohn, J.; Kumar, R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. *J. Biol. Chem.* 1998, 273, 1568–1573.

64. Huang, S.M.; Harari, P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. *Clin. Cancer Res.* 2000, 6, 2166–2174.

65. Yacoub, A.; McKinstry, R.; Hinman, D.; Chung, T.; Dent, P.; Hagan, M.P. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. *Radiat. Res.* 2003, 159, 439–452.

66. Dittmann, K.; Mayer, C.; Rodemann, H.P. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. *Radiother. Oncol.* 2005, 76, 157–161.

67. Dittmann, K.; Mayer, C.; Fehrenbacher, B.; Schaller, M.; Raju, U.; Milas, L.; Chen, D.J.; Kehlbach, R.; Rodemann, H.P. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. *J. Biol. Chem.* 2005, 280, 31182–31189.

68. Li, L.; Wang, H.; Yang, E.S.; Arteaga, C.L.; Xia, F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. *Cancer Res.* 2008, 68, 9141–9146.

69. Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N. Engl. J. Med.* 2006, 354, 567–578.
70. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N. Engl. J. Med.* **2004**, *350*, 2129–2139.

71. Bell, D.W.; Lynch, T.J.; Haserlat, S.M.; Harris, P.L.; Okimoto, R.A.; Brannigan, B.W.; Sgroi, D.C.; Muir, B.; Riemenschneider, M.J.; Iacona, R.B.; et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. *J. Clin. Oncol.* **2005**, *23*, 8081–8092.

72. Shigematsu, H.; Gazdar, A.F. Somatic mutations of epidermal growth factor signaling pathway in lung cancers. *Int. J. Cancer* **2006**, *118*, 257–262.

73. Amann, J.; Kalyankrishna, S.; Massion, P.P.; Ohm, J.E.; Girard, L.; Shigematsu, H.; Peyton, M.; Juroske, D.; Huang, Y.; Stuart Salmon, J.; et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. *Cancer Res.* **2005**, *65*, 226–235.

74. Arao, T.; Fukumoto, H.; Takeda, M.; Tamura, T.; Saijo, N.; Nishio, K. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. *Cancer Res.* **2004**, *64*, 9101–9104.

75. Engelman, J.A.; Janne, P.A.; Mermel, C.; Pearlberg, J.; Mukohara, T.; Fleet, C.; Ciehowski, K.; Johnson, B.E.; Cantley, L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 3788–3793.

76. Sordella, R.; Bell, D.W.; Haber, D.A.; Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. *Science* **2004**, *305*, 1163–1167.

77. Das, A.K.; Sato, M.; Story, M.D.; Peyton, M.; Graves, R.; Redpath, S.; Girard, L.; Gazdar, A.F.; Shay, J.W.; Minna, J.D.; et al. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. *Cancer Res.* **2006**, *66*, 9601–9608.

78. Das, A.K.; Chen, B.P.; Story, M.D.; Sato, M.; Minna, J.D.; Chen, D.J.; Nirodi, C.S. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. *Cancer Res.* **2007**, *67*, 5267–5274.

79. Miller, B.S.; Yee, D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. *Cancer Res.* **2005**, *65*, 10123–10127.

80. Larsson, O.; Girnita, A.; Girnita, L. Role of insulin-like growth factor 1 receptor signalling in cancer. *Br. J. Cancer* **2005**, *92*, 2097–2101.

81. Pollak, M.N.; Schernhammer, E.S.; Hankinson, S.E. Insulin-like growth factors and neoplasia. *Nat. Rev. Cancer* **2004**, *4*, 505–518.

82. Tao, Y.; Pinzi, V.; Bourhis, J.; Deutsch, E. Mechanisms of disease: Signaling of the insulin-like growth factor 1 receptor pathway—Therapeutic perspectives in cancer. *Nat. Clin. Pract. Oncol.* **2007**, *4*, 591–602.

83. Werner, H.; Le Roith, D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. *Crit. Rev. Oncog.* **1997**, *8*, 71–92.
84. Turner, B.C.; Haffty, B.G.; Narayanan, L.; Yuan, J.; Havre, P.A.; Gumbs, A.A.; Kaplan, L.; Burgaud, J.L.; Carter, D.; Baserga, R.; et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. *Cancer Res.* 1997, 57, 3079–3083.

85. Macaulay, V.M.; Salisbury, A.J.; Bohula, E.A.; Playford, M.P.; Smorodinsky, N.I.; Shiloh, Y. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. *Oncogene* 2001, 20, 4029–4040.

86. Peretz, S.; Jensen, R.; Baserga, R.; Glazer, P.M. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. *Proc. Natl. Acad. Sci. USA* 2001, 98, 1676–1681.

87. Rotman, G.; Shiloh, Y. ATM: A mediator of multiple responses to genotoxic stress. *Oncogene* 1999, 18, 6135–6144.

88. Trojanek, J.; Ho, T.; del Valle, L.; Nowicki, M.; Wang, J.Y.; Lassak, A.; Peruzzi, F.; Khalili, K.; Skorski, T.; Reiss, K. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. *Mol. Cell Biol.* 2003, 23, 7510–7524.

89. Allen, G.W.; Saba, C.; Armstrong, E.A.; Huang, S.M.; Benavente, S.; Ludwig, D.L.; Hicklin, D.J.; Harari, P.M. Insulin-like growth factor-I receptor signaling blockade combined with radiation. *Cancer Res.* 2007, 67, 1155–1162.

90. Riesterer, O.; Yang, Q.; Raju, U.; Torres, M.; Molkentine, D.; Patel, N.; Valdecanas, D.; Milas, L.; Ang, K.K. Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers. *Int. J. Radiat. Oncol. Biol. Phys.* 2011, 79, 1179–1187.

91. Laird, A.D.; Vajkoczy, P.; Shawver, L.K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S.R.; Blake, R.A.; et al. Cherrington SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. *Cancer Res.* 2000, 60, 4152–4160.

92. Griffin, R.J.; Williams, B.W.; Wild, R.; Cherrington, J.M.; Park, H.; Song, C.W. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. *Cancer Res.* 2002, 62, 1702–1706.

93. Ning, S.; Laird, D.; Cherrington, J.M.; Knox, S.J. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. *Radiat. Res.* 2002, 157, 45–51.

94. Abdollahi, A.; Lipson, K.E.; Han, X.; Krempien, R.; Trinh, T.; Weber, K.J.; Hahnfeldt, P.; Hlatky, L.; Debus, J.; Howlett, A.R.; et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. *Cancer Res.* 2003, 63, 3755–3763.

95. Fong, T.A.; Shawver, L.K.; Sun, L.; Tang, C.; App, H.; Powell, T.J.; Kim, Y.H.; Schreck, R.; Wang, X.; Risau, W.; et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. *Cancer Res.* 1999, 59, 99–106.
96. Mendel, D.B.; Laird, A.D.; Smolich, B.D.; Blake, R.A.; Liang, C.; Hannah, A.L.; Shaheen, R.M.; Ellis, L.M.; Weitman, S.; Shawver, L.K.; et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. *Anticancer Drug Des.* **2000**, *15*, 29–41.

97. Timke, C.; Zieher, H.; Roth, A.; Hauser, K.; Lipson, K.E.; Weber, K.J.; Debus, J.; Abdollahi, A.; Huber, P.E. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. *Clin. Cancer Res.* **2008**, *14*, 2210–2219.

98. De Bacco, F.; Luraghi, P.; Medico, E.; Reato, G.; Girolami, F.; Perera, T.; Gabriele, P.; Comoglio, P.M.; Boccaccio, C. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. *J. Natl. Cancer Inst.* **2011**, *103*, 645–661.

99. Medova, M.; Aebersold, D.M.; Blank-Liss, W.; Streit, B.; Medo, M.; Aebi, S.; Zimmer, Y. MET inhibition results in DNA breaks and synergistically sensitizes tumor cells to DNA-damaging agents potentially by breaching a damage-induced checkpoint arrest. *Genes Cancer* **2010**, *1*, 1053–1062.

100. Ganapathipillai, S.S.; Medova, M.; Aebersold, D.M.; Manley, P.W.; Berthou, S.; Streit, B.; Blank-Liss, W.; Greiner, R.H.; Rothen-Rutishauser, B.; Zimmer, Y. Coupling of mutated Met variants to DNA repair via Abl and Rad51. *Cancer Res.* **2008**, *68*, 5769–5777.

101. Maroun, C.R.; Moscatello, D.K.; Naujokas, M.A.; Holgado-Madruga, M.; Wong, A.J.; Park, M. A conserved inositol phospholipid binding site within the pleckstrin homology domain of the Gab1 docking protein is required for epithelial morphogenesis. *J. Biol. Chem.* **1999**, *274*, 31719–31726.

102. Welsh, J.W.; Mahadevan, D.; Ellsworth, R.; Cooke, L.; Bearss, D.; Stea, B. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. *Radiat. Oncol.* **2009**, *4*, 69.

103. Fan, S.; Wang, J.A.; Yuan, R.Q.; Rockwell, S.; Andres, J.; Zlatapolskiy, A.; Goldberg, I.D.; Rosen, E.M. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. *Oncogene* **1998**, *17*, 131–141.

104. Fan, S.; Ma, Y.X.; Wang, J.A.; Yuan, R.Q.; Meng, Q.; Cao, Y.; Laterra, J.J.; Goldberg, I.D.; Rosen, E.M. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidylinositol 3’ kinase. *Oncogene* **2000**, *19*, 2212–2223.

105. Yuan, R.; Fan, S.; Achary, M.; Stewart, D.M.; Goldberg, I.D.; Rosen, E.M. Altered gene expression pattern in cultured human breast cancer cells treated with hepatocyte growth factor/scatter factor in the setting of DNA damage. *Cancer Res.* **2001**, *61*, 8022–8031.
108. Sheng-Hua, C.; Yan-Bin, M.; Zhi-An, Z.; Hong, Z.; Dong-Fu, F.; Zhi-Qiang, L.; Xian-Hou, Y. Radiation-enhanced hepatocyte growth factor secretion in malignant glioma cell lines. Surg. Neurol. 2007, 68, 610–613.

109. Qian, L.W.; Mizumoto, K.; Inadome, N.; Nagai, E.; Sato, N.; Matsumoto, K.; Nakamura, T.; Tanaka, M. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int. J. Cancer 2003, 104, 542–549.

110. Goetsch, L.; Caussanel, V.; Corvaia, N. Biological significance and targeting of c-Met tyrosine kinase receptor in cancer. Front. Biosci. (Landmark Ed.) 2013, 18, 454–473.

111. Peters, S.; Adjei, A.A. MET: A promising anticancer therapeutic target. Nat. Rev. Clin. Oncol. 2012, 9, 314–326.

112. Aebersold, D.M.; Kollar, A.; Beer, K.T.; Laissue, J.; Greiner, R.H.; Djonov, V. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bel-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int. J. Cancer 2001, 96, 41–54.

113. Kim, Y.J.; Go, H.; Wu, H.G.; Jeon, Y.K.; Park, S.W.; Lee, S.H. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck 2011, 33, 1458–1466.

114. Gao, J.; Inagaki, Y.; Song, P.; Qu, X.; Kokudo, N.; Tang, W. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol. Res. 2012, 65, 23–30.

115. Raghav, K.P.; Wang, W.; Liu, S.; Chavez-MacGregor, M.; Meng, X.; Hortobagyi, G.N.; Mills, G.B.; Meric-Bernstam, F.; Blumenschein, G.R., Jr.; Gonzalez-Angulo, A.M. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin. Cancer Res. 2012, 18, 2269–2277.

116. Kim, C.H.; Koh, Y.W.; Han, J.H.; Kim, J.W.; Lee, J.S.; Baek, S.J.; Hwang, H.S.; Choi, E.C. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck 2010, 32, 1655–1664.

117. Di Renzo, M.F.; Olivero, M.; Martone, T.; Maffè, A.; Maggiora, P.; Stefani, A.D.; Valente, G.; Giordano, S.; Cortesina, G.; Comoglio, P.M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000, 19, 1547–1555.

118. Aebersold, D.M.; Landt, O.; Berthou, S.; Gruber, G.; Beer, K.T.; Greiner, R.H.; Zimmer, Y. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 2003, 22, 8519–8523.

119. Sattler, M.; Reddy, M.M.; Hasina, R.; Gangadhar, T.; Salgia, R. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther. Adv. Med. Oncol. 2011, 3, 171–184.

120. Eder, J.P.; vande Woude, G.F.; Boerner, S.A.; LoRusso, P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 2009, 15, 2207–2214.

121. Lal, B.; Xia, S.; Abounader, R.; Laterra, J. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin. Cancer Res. 2005, 11, 4479–4486.

122. Chu, S.H.; Zhu, Z.A.; Yuan, X.H.; Li, Z.Q.; Jiang, P.C. In vitro and in vivo potentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides. J. Neurooncol. 2006, 80, 143–149.
123. Yu, H.; Li, X.; Sun, S.; Gao, X.; Zhou, D. c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. *Biochem. Biophys. Res. Commun.* **2012**, *427*, 659–665.

124. Bhardwaj, V.; Zhan, Y.; Cortez, M.A.; Ang, K.K.; Molkentine, D.; Munshi, A.; Raju, U.; Komaki, R.; Heymach, J.V.; Welsh, J. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. *J. Thorac. Oncol.* **2012**, *7*, 1211–1217.

125. Lin, C.I.; Whang, E.E.; Donner, D.B.; Du, J.; Lorch, J.; He, F.; Jiang, X.; Price, B.D.; Moore, F.D., Jr.; Ruan, D.T. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. *Mol. Cancer Res.* **2010**, *8*, 1217–1226.

126. Buchanan, I.M.; Scott, T.; Tandle, A.T.; Burgan, W.E.; Burgess, T.L.; Tofilon, P.J.; Camphausen, K. Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. *J. Cell. Mol. Med.* **2011**, *15*, 1999–2006.

127. Khanna, K.K.; Jackson, S.P. DNA double-strand breaks: Signaling, repair and the cancer connection. *Nat. Genet.* **2001**, *27*, 247–254.

128. Chen, G.; Yuan, S.S.; Liu, W.; Xu, Y.; Trujillo, K.; Song, B.; Cong, F.; Goff, S.P.; Wu, Y.; Arlinghaus, R.; *et al*. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. *J. Biol. Chem.* **1999**, *274*, 12748–12752.

129. Takizawa, Y.; Kinebuchi, T.; Kagawa, W.; Yokoyama, S.; Shibata, T.; Kurumizaka, H. Mutational analyses of the human Rad51-Tyr315 residue, a site for phosphorylation in leukaemia cells. *Genes Cells* **2004**, *9*, 781–790.

130. Cook, P.J.; Ju, B.G.; Telese, F.; Wang, X.; Glass, C.K.; Rosenfeld, M.G. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. *Nature* **2009**, *458*, 591–596.

131. Xiao, A.; Li, H.; Shechter, D.; Ahn, S.H.; Fabrizio, L.A.; Erjument-Bromage, H.; Ishibe-Murakami, S.; Wang, B.; Tempst, P.; Hofmann, K.; *et al*. WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. *Nature* **2009**, *457*, 57–62.

132. Brahimi-Horn, M.C.; Chiche, J.; Pouyssegur, J. Hypoxia and cancer. *J. Mol. Med. (Berl.)* **2007**, *85*, 1301–1307.

133. Brahimi-Horn, M.C.; Chiche, J.; Pouyssegur, J. Hypoxia signalling controls metabolic demand. *Curr. Opin. Cell Biol.* **2007**, *19*, 223–229.

134. Jain, R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. *Science* **2005**, *307*, 58–62.

135. Harris, A.L. Hypoxia—A key regulatory factor in tumour growth. *Nat. Rev. Cancer* **2002**, *2*, 38–47.

136. Brizel, D.M.; Sibley, G.S.; Prosnitz, L.R.; Scher, R.L.; Dewhirst, M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. *Int. J. Radiat. Oncol. Biol. Phys.* **1997**, *38*, 285–289.

137. Hockel, M.; Schlenker, K.; Aral, B.; Mitze, M.; Schaffer, U.; Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. *Cancer Res.* **1996**, *56*, 4509–4515.
138. Kaanders, J.H.; Wijffels, K.I.; Marres, H.A.; Ljungkvist, A.S.; Pop, L.A.; van den Hoogen, F.J.; de Wilde, P.C.; Bussink, J.; Raleigh, J.A.; van der Kogel, A.J. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. *Cancer Res.* **2002**, *62*, 7066–7074.

139. Nordsmark, M.; Bentzen, S.M.; Rudat, V.; Brizel, D.; Lartigau, E.; Stadler, P.; Becker, A.; Adam, M.; Molls, M.; Dunst, J.; *et al.* Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. *Radiother. Oncol.* **2005**, *77*, 18–24.

140. Vaupel, P. Tumor microenvironmental physiology and its implications for radiation oncology. *Semin. Radiat. Oncol.* **2004**, *14*, 198–206.

141. Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. *Cell Metab.* **2006**, *3*, 177–185.

142. Bindra, R.S.; Schaffer, P.J.; Meng, A.; Woo, J.; Maseide, K.; Roth, M.E.; Lizardi, P.; Hedley, D.W.; Bristow, R.G.; Glazer, P.M. Alterations in DNA repair gene expression under hypoxia: Elucidating the mechanisms of hypoxia-induced genetic instability. *Ann. N. Y. Acad. Sci.* **2005**, *1059*, 184–195.

143. Tang, N.; Wang, L.; Esko, J.; Giordano, F.J.; Huang, Y.; Gerber, H.P.; Ferrara, N.; Johnson, R.S. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. *Cancer Cell* **2004**, *6*, 485–495.

144. Gustafsson, M.V.; Zheng, X.; Pereira, T.; Gradin, K.; Jin, S.; Lundkvist, J.; Ruas, J.L.; Poellinger, L.; Lendahl, U.; Bondesson, M. Hypoxia requires notch signaling to maintain the undifferentiated cell state. *Dev. Cell* **2005**, *9*, 617–628.

145. Tredan, O.; Galmarini, C.M.; Patel, K.; Tannock, I.F. Drug resistance and the solid tumor microenvironment. *J. Natl. Cancer Inst.* **2007**, *99*, 1441–1454.

146. Hockel, M.; Vaupel, P. Biological consequences of tumor hypoxia. *Semin. Oncol.* **2001**, *28*, 36–41.

147. Hockel, M.; Vaupel, P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. *J. Natl. Cancer Inst.* **2001**, *93*, 266–276.

148. Nordsmark, M.; Overgaard, M.; Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. *Radiother. Oncol.* **1996**, *41*, 31–39.

149. Gatenby, R.A.; Kessler, H.B.; Rosenblum, J.S.; Coia, L.R.; Moldofsky, P.J.; Hartz, W.H.; Broder, G.J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* **1988**, *14*, 831–838.

150. Brizel, D.M.; Dodge, R.K.; Clough, R.W.; Dewhirst, M.W. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. *Radiother. Oncol.* **1999**, *53*, 113–117.

151. Aebersold, D.M.; Burri, P.; Beer, K.T.; Laissue, J.; Djonov, V.; Greiner, R.H.; Semenza, G.L. Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. *Cancer Res.* **2001**, *61*, 2911–2916.
Bachtiary, B.; Schindl, M.; Potter, R.; Dreier, B.; Knocke, T.H.; Hainfellner, J.A.; Horvat, R.; Birner, P. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. *Clin. Cancer Res.* **2003**, *9*, 2234–2240.

Trusolino, L.; Bertotti, A.; Comoglio, P.M. MET signalling: Principles and functions in development, organ regeneration and cancer. *Nat. Rev. Mol. Cell Biol.* **2010**, *11*, 834–848.

Hara, S.; Nakashiro, K.; Klosek, S.K.; Ishikawa, T.; Shintani, S.; Hamakawa, H. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. *Oral Oncol.* **2006**, *42*, 593–598.

Chen, H.H.; Su, W.C.; Lin, P.W.; Guo, H.R.; Lee, W.Y. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. *Breast Cancer Res. Treat.* **2007**, *103*, 167–175.

Scarpino, S.; Cancellario d'Alena, F.; Di Napoli, A.; Pasquini, A.; Marzullo, A.; Ruco, L.P. Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. *J. Pathol.* **2004**, *202*, 352–358.

Ide, T.; Kitajima, Y.; Miyoshi, A.; Ohtsuka, T.; Mitsuno, M.; Ohtaka, K.; Koga, Y.; Miyazaki, K. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. *Int. J. Cancer* **2006**, *119*, 2750–2759.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).